We use cookies on our site to analyze traffic, enhance your experience, and provide you with tailored content.

For more information visit our privacy policy.

0001104659-16-105686 Sample Contracts

Standard Contracts

AGREEMENT BETWEEN: ADAPTIMMUNE LIMITED (1) and UNIVERSAL CELLS, INC. (2)
Research Collaboration and License Agreement • March 17th, 2016 • Adaptimmune Therapeutics PLC • Biological products, (no disgnostic substances) • England

This RESEARCH COLLABORATION AND LICENCE AGREEMENT (the “Agreement”) is made as of the 25th day of November 2015 (the “Effective Date”) by and between:

Contract
Amendment Agreement No. 2 • March 17th, 2016 • Adaptimmune Therapeutics PLC • Biological products, (no disgnostic substances)

***Certain portions of this exhibit have been omitted based on a request for confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended. The omitted portions have been filed separately with the Securities and Exchange Commission.

NON-EXCLUSIVE SUB-LICENSE AGREEMENT
Non-Exclusive Sub-License Agreement • March 17th, 2016 • Adaptimmune Therapeutics PLC • Biological products, (no disgnostic substances) • Washington

THIS AGREEMENT (“Agreement”) is dated and effective as of the date of last signature (“Effective Date”), and is made by and between Universal and Adaptimmune Limited, an English Adaptimmune with principal offices at 101 Park Drive, Milton Park, Abingdon, Oxfordshire, OX14 4RY (“Adaptimmune”), and Universal Cells, a Corporation under the laws of the state of Washington (“Universal”) with principal offices at 720 Broadway, Seattle, WA 98122, agree as follows:

Contract
Hla/Aav Sublicence • March 17th, 2016 • Adaptimmune Therapeutics PLC • Biological products, (no disgnostic substances) • Washington

***Certain portions of this exhibit have been omitted based on a request for confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended. The omitted portions have been filed separately with the Securities and Exchange Commission.

Contract
Amendment Agreement • March 17th, 2016 • Adaptimmune Therapeutics PLC • Biological products, (no disgnostic substances)

***Certain portions of this exhibit have been omitted based on a request for confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended. The omitted portions have been filed separately with the Securities and Exchange Commission.